
    
      The purpose of this study is to determine progression-free survival (PFS) in participants
      with unresectable hepatocellular carcinoma who have received no prior systemic therapy when
      treated with IMC-A12 administered every three weeks in combination with oral sorafenib
      administered twice daily.
    
  